Display options
Cite
Liu ZH, Zhang Q, Ding YJ, et al. Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma. Oncotarget. 2017;8(43):74178-74187doi: 10.18632/oncotarget.18830.
Liu, Z. H., Zhang, Q., Ding, Y. J., Ren, Y. H., Yang, H. P., Xi, Q., Cheng, Y. N., Miao, G. L., Liu, H. K., Li, C. X., Yan, W. Q., Li, Y., Xue, Z., Zhang, L., Li, X. Y., Zhao, C. L., Da, Y., Wu, X. Z., Chen, J. Q., Zhang, R., & Li, Z. G. (2017). Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma. Oncotarget, 8(43), 74178-74187. https://doi.org/10.18632/oncotarget.18830
Liu, Ze-Han, et al. "Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma." Oncotarget vol. 8,43 (2017): 74178-74187. doi: https://doi.org/10.18632/oncotarget.18830
Liu ZH, Zhang Q, Ding YJ, Ren YH, Yang HP, Xi Q, Cheng YN, Miao GL, Liu HK, Li CX, Yan WQ, Li Y, Xue Z, Zhang L, Li XY, Zhao CL, Da Y, Wu XZ, Chen JQ, Zhang R, Li ZG. Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma. Oncotarget. 2017 Jun 29;8(43):74178-74187. doi: 10.18632/oncotarget.18830. eCollection 2017 Sep 26. PMID: 29088777; PMCID: PMC5650332.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jun 29;8(43):74178-74187. doi: 10.18632/oncotarget.18830. eCollection 2017 Sep 26.

Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma.

Oncotarget

Ze-Han Liu, Qi Zhang, Yi-Jie Ding, Ying-Hui Ren, Hui-Peng Yang, Qing Xi, Ying-Nan Cheng, Guo-Lin Miao, Hong-Kun Liu, Cai-Xia Li, Wen-Qiang Yan, Yan Li, Zhenyi Xue, Lijuan Zhang, Xin-Ye Li, Chen-Long Zhao, Yurong Da, Xian-Zhong Wu, Jun-Qiang Chen, Rongxin Zhang, Zhi-Gang Li

Affiliations

  1. Nankai Clinical College, Tianjin Medical University, Tianjin, P.R. China.
  2. Institute of Integrative Medicine Therapy for Acute Abdominal Diseases of Tianjin, Nankai Hospital, Tianjin, P. R. China.
  3. Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Basic Medical College, Tianjin Medical University, Tianjin, P.R. China.
  4. First Central Clinical College, Tianjin Medical University, Tianjin, P.R. China.
  5. Department of Thoracic Surgery, Nankai Hospital, Nankai District, Tianjin, P. R. China.
  6. General Hospital, Tianjin Medical University, Tianjin, P.R. China.
  7. Department of Radiotherapy, Fujian Provincial Tumor Hospital, Affiliated Tumor Hospital of Fujian Medical University, Fuzhou, P.R. China.
  8. Laboratory of Immunology and Inflammation, Guangdong Pharmaceutical University, Guangzhou, P.R. China.
  9. Hainan Cancer Hospital, Affiliated Cancer Hospital of Hainan Medical College, Haikou City, P.R. China.

PMID: 29088777 PMCID: PMC5650332 DOI: 10.18632/oncotarget.18830

Abstract

Esophageal carcinoma (EC) is a malignancy with high metastatic potential. Chromosomal helicase/ATPase DNA binding protein 1-like (CHD1L) gene is a newly identified oncogene located at Chr1q21, and it is amplified in many solid tumors. However, the status of CHD1L protein expression in EC and its clinical significance is uncertain. This study was designed to investigate the significance of CHD1L expression in human EC and its biological function in EC cells. The expression of CHD1L was examined by immunohistochemistry in 191 surgically resected ECs. The associations between CHD1L expression and clinical pathological parameters and the prognostic value of CHD1L were analyzed. Western blot analysis showed that CHD1L was overexpressed in EC cell lines. In addition, positive CHD1L expression was strongly related to advanced clinical stage (

Keywords: CHD1L protein; apoptosis; esophageal carcinoma; migration; prognosis

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest in this work.

References

  1. Oncotarget. 2017 Jan 17;8(3):5566-5577 - PubMed
  2. Cell. 1997 Mar 21;88(6):737-40 - PubMed
  3. Oncotarget. 2015 Oct 13;6(31):31181-90 - PubMed
  4. J Gastrointest Oncol. 2015 Feb;6(1):60-74 - PubMed
  5. Oncotarget. 2015 Oct 27;6(33):34228-44 - PubMed
  6. Clin Transl Oncol. 2014 Aug;16(8):702-7 - PubMed
  7. J Clin Invest. 2010 Apr;120(4):1178-91 - PubMed
  8. Oncologist. 2013;18(7):823-32 - PubMed
  9. Gastroenterology. 2016 May;150(5):1171-1182 - PubMed
  10. PLoS One. 2014 Aug 25;9(8):e98673 - PubMed
  11. Nat Genet. 2014 Oct;46(10):1097-102 - PubMed
  12. Hepatology. 2008 Feb;47(2):503-10 - PubMed
  13. PLoS One. 2012;7(8):e42281 - PubMed
  14. Nat Struct Mol Biol. 2005 Feb;12(2):160-6 - PubMed
  15. J Surg Res. 2013 Nov;185(1):84-91 - PubMed
  16. Oncotarget. 2016 Jul 26;7(30):48644-48655 - PubMed
  17. Nat Genet. 2014 Aug;46(8):837-843 - PubMed
  18. Nature. 2014 May 1;509(7498):91-5 - PubMed
  19. Cancer Res. 2004 Dec 1;64(23):8541-9 - PubMed
  20. Exp Ther Med. 2014 Dec;8(6):1745-1750 - PubMed
  21. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  22. Curr Opin Chem Biol. 2011 Oct;15(5):649-56 - PubMed
  23. BMC Cancer. 2012 Sep 29;12:437 - PubMed
  24. Tumour Biol. 2013 Dec;34(6):3687-90 - PubMed
  25. Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11472-7 - PubMed
  26. Asian J Surg. 2016 Dec 13;:null - PubMed
  27. Gut. 2011 Apr;60(4):534-43 - PubMed
  28. Nat Rev Cancer. 2003 Jun;3(6):453-8 - PubMed
  29. Lancet. 2007 May 19;369(9574):1742-57 - PubMed
  30. Korean J Pathol. 2013 Feb;47(1):9-15 - PubMed
  31. Cancer Res. 2012 Sep 1;72(17):4383-93 - PubMed

Publication Types